For Southeast Asian manufacturers looking to export medical disinfection products like iodine prep pads, alcohol swabs, and cotton swabs to Europe, CE certification is not optional—it's the legal gateway to market access. The Medical Device Regulation (MDR) EU 2017/745, which fully replaced the old Medical Device Directive (MDD 93/42/EEC), has significantly tightened compliance requirements since its implementation.
What CE Certification Actually Means: CE marking demonstrates that a medical device conforms with EU health, safety, and environmental protection legislation. For disposable medical consumables like iodine pads and alcohol swabs, this typically falls under Class I (low risk) or Class IIa (medium risk) depending on intended use and claims made. The certification process involves technical documentation, conformity assessment, and ongoing post-market surveillance.
Key MDR Requirements for 2026: The transition period for legacy devices has been extended multiple times, with Class III devices facing a December 31, 2027 deadline for full MDR compliance. However, all new products entering the EU market must comply with MDR from day one. Critical requirements include: technical documentation per Annex II & III, Declaration of Conformity, EU Authorized Representative (for non-EU manufacturers), EUDAMED database registration, Unique Device Identification (UDI) system implementation, and Post-Market Surveillance Reports (PSUR).
CE mark demonstrates conformity with EU legislation. Technical documentation Annex II&III MDR required, Declaration of Conformity mandatory, post-market surveillance PSUR required, UDI (Unique Device Identification) system implementation, EU Authorized Representative required for non-EU manufacturers. [2]
The Notified Body Bottleneck: One of the most significant challenges in 2026 is the shortage of Notified Bodies—organizations designated by EU member states to assess conformity of certain products before being placed on the market. This capacity vs workload imbalance creates delays, particularly for Class IIa and above devices. Industry analysis indicates that approximately 35,000 in vitro diagnostic devices are covered by Notified Bodies for the first time under IVDR, adding further pressure to an already constrained system.

